Immune to Cancer: The CRI Blog
-
How COVID-19 is Impacting Care for Lung Cancer Patients
CRI spoke with Dr. Joshua Sabari about how clinical care for lung cancer patients has been impacted…
-
AACR20 Day 1 Highlights: Breast Cancer, Lung Cancer, and the Microbiome
The first day of the 2020 AACR Annual Meeting shared latest data from immunotherapy clinical trials in…
-
How Immunotherapy for Esophageal Cancer is Making an Impact
Dr. Deirdre Cohen discusses recent advances in immunotherapy for esophageal cancer, including biomarkers, checkpoint inhibitors, cell-based therapies,…
-
Defining Resistance to Treatment with Anti-PD-1/PD-L1 Immunotherapy
CRI's Vanessa M. Lucey, Ph.D, MBA, helps guide the design and analysis of future clinical trials involving…
-
Pancreatic Cancer, Immunotherapy, and PRINCE: An Interview with Vanessa Lucey, PhD, MBA
We spoke with Vanessa M. Lucey, PhD, MBA, about challenges of treating pancreatic cancer and promising combination therapy…
-
Gordon Levine’s Immunotherapy Experience: A New Understanding of Advocacy
Colorectal cancer veteran Gordon Levine discusses genomic testing, clinical trials, patient advocacy, and access to immunotherapy.
-
PORTER Immunotherapy Clinical Trial for Prostate Cancer Unveiled at SITC2019
Details of a promising new CRI co-funded clinical trial for metastatic prostate cancer unveiled at the 2019…
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…
-
ASCO19 Day 3 Update: Immunotherapy for Brain Cancer, Ovarian Cancer, Lung Cancer, and Patients with HIV
The third day at ASCO19 highlighted immunotherapy strategies for patients with brain cancer, ovarian cancer, lung cancer,…